Clinical Trial

Pharmacokinetics, Efficacy, and Safety of Encaleret in Pediatric Participants With Autosomal Dominant Hypocalcemia Type 1 (ADH1)

Study acronym: CALIBRATE-PEDS
Recruiting Phase 2/3
View on ClinicalTrials.gov →
Summary
The overall objective of this study is to evaluate the pharmacokinetics (PK), efficacy, and safety of encaleret in pediatric participants from birth to 17 years of age with ADH1.
Protocol Amendment History 6 amendments
This ClinicalTrials.gov record has been amended 6 times since 2025-07-14; most recent amendment 2026-04-20.
Status change: Not Yet Recruiting → Recruiting 2026-01-13
Trial Details
NCT Number NCT07080385
Lead Sponsor Calcilytix Therapeutics, Inc., a BridgeBio company
Conditions Autosomal Dominant Hypocalcemia Type 1 (ADH1)
Enrollment 28 participants
Start Date 2026-01-30
Primary Completion 2028-12 (estimated)
Study Completion 2030-12 (estimated)
Updated on ClinicalTrials.gov 2026-04-22